Aseem Malhotra
Aseem Malhotra is a medical researcher working in the fields of cardiovascular health and clinical nutrition. His published research examines coronary artery disease interventions, including the clinical roles of coronary stents, statin therapy, and target cholesterol levels. He has also published work evaluating dietary strategies for type 2 diabetes remission and the relationship between lifestyle factors, inflammation, and cardiovascular disease.
13 claims checked on air: 1 context 3 contradicted 1 overstated 8 supported
What they said on air - supported
3 citing their own research
Saturated fat consumption raises LDL cholesterol.
"and we know saturated fat raises LDL cholesterol" (said at 0:44:24)
Extensive randomized controlled trial evidence and systematic reviews consistently show that consumption of saturated fatty acids increases circulating LDL cholesterol (and conversely, reducing dietary saturated fat or replacing it with unsaturated fats lowers total and LDL cholesterol).
- supports: Reduction in saturated fat intake for cardiovascular disease. (The Cochrane database of systematic reviews 2020)
"There was little or no effect on cancer mortality, cancer diagnoses, diabetes diagnosis, HDL cholesterol, serum triglycerides or blood pressure, and small reductions in weight, serum total cholesterol, LDL cholesterol and BMI." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of Replacement of Individual Dietary SFAs on Circulating Lipids and Other Biomarker… (Advances in nutrition (Bethesda, Md.) 2022) · cited 38x in the literature
"We observed reductions in LDL-cholesterol concentrations after the replacement of palmitic acid (16:0) with UFAs (-0.36 mmol/L; 95% CI: -0.50, -0.21 mmol/L; I2 = 96.0%, n = 18 RCTs) or oleic acid (18:1n-9) (-0.16 mmol/L; 95% CI: -0.28, -0.03 mmol/L; I2 = 89.6%, n = 9 RCTs), with a similar impact on total cholesterol and apoB concentrations." (abstract, results, passage verified)
pubmedfull study (doi)
Statins exhibit distinct anti-inflammatory and anti-clotting mechanisms independent of cholesterol lowering.
"statins had a separate effect to lower cholesterol, which is their anti-inflammatory and their anti-clotting." (said at 0:44:33)
The claim is supported. Extensive clinical and mechanistic literature confirms that HMG-CoA reductase inhibitors (statins) exert well-established 'pleiotropic' effects independent of their primary low-density lipoprotein (LDL) cholesterol-lowering pathway. By inhibiting the mevalonate pathway and the isoprenylation of small GTP-binding proteins (such as Rho, Ras, and Rac), statins mediate distinct anti-inflammatory effects (e.g., reductions in hs-CRP, proinflammatory cytokines, and leukocyte adhesion) and antithrombotic/anti-clotting effects (e.g., attenuation of tissue factor expression, inhibition of platelet activation and thrombus formation, and modulation of fibrin clot properties).
The Framingham Heart Study began longitudinal data collection in Massachusetts in 1948.
"So these are the Framingham studies that, uh, you know, started in Massachusetts in 1948 and went over decades looking at thousands of people" (said at 0:46:54)
The statement is accurate. The Framingham Heart Study is the longest-running cardiovascular epidemiological cohort study; it was established in 1948 in Framingham, Massachusetts, collecting longitudinal data over multiple generations across several decades.
A systematic review of over 30 randomized controlled trials found no clear relationship between the degree of LDL reduction from cholesterol-lowering drugs and prevention of cardiovascular events.
"So myself and two cardiologists did a systematic review of the totality of drug industry-sponsored trials, by the way, and some diet trials, but many drug industry-sponsored trials, all of the randomized controlled trials on cholesterol-lowering drugs: statins, PCSK9, blah, blah. Was there a clear relationship as you lowered LDL in low-risk and high-risk patients, Mark, okay, over 30 studies, was there a relationship with lowering LDL and preventing cardiovascular events? No." (said at 0:48:30)
The speaker accurately describes the findings of a published systematic review of 35 randomized controlled trials (PMID 32747335), which he co-authored. The review analyzed trials evaluating LDL cholesterol targets across diverse risk populations and concluded that achieving specific LDL target levels through drug therapy did not confer consistent cardiovascular benefit, questioning the direct relationship between LDL-C lowering as a surrogate target and cardiovascular event reduction. A subsequent 2022 systematic review and meta-regression in JAMA Internal Medicine (PMID 35285850) evaluating statin trials similarly concluded that a conclusive relationship between the magnitude of absolute LDL-C reduction and individual clinical outcomes (all-cause mortality, myocardial infarction, stroke) was not established.
A 2016 systematic review of observational cohort studies in people over age 60 found an inverse association between LDL cholesterol and all-cause mortality.
"2016, and the reason we did this, me and a number of international scientists, we decided to do a systematic review of observational data looking at people over 60. ... but what was surprising was there was an inverse association with LDL cholesterol and all-cause mortality. In other words, statistically, if you're over 60, the higher LDL, the less likely you are to die." (said at 0:54:26)
A 2016 systematic review by Ravnskov et al. (published in BMJ Open) evaluated 19 cohort studies comprising 30 cohorts and 68,094 participants aged 60 years and older. The authors reported an inverse association between LDL cholesterol and all-cause mortality in 16 of the 28 cohorts where all-cause mortality was recorded (representing 92% of analyzed participants), with no association found in the remaining cohorts. Because the underlying evidence base consists of observational cohort studies susceptible to reverse causation (e.g., frailty, terminal illness, or malnutrition lowering cholesterol levels prior to death) and residual confounding, the certainty of evidence for this observational association is low.
In the Framingham Heart Study, after age 50, mortality increased as total cholesterol dropped.
"another thing that was interesting from Framingham which wasn't well publicized is that when after people hit 50 years old, as their cholesterol dropped, their mortality increased." (said at 0:54:40)
Published analyses of the Framingham Heart Study support the statement. In a 30-year follow-up analysis of Framingham participants published in JAMA (1987), researchers reported that for individuals over age 50, falling total cholesterol levels over a 14-year period were associated with an 11% increase in overall mortality and a 14% increase in cardiovascular mortality for every 1 mg/dL per year decrease in cholesterol. A subsequent 1993 analysis confirmed that total cholesterol was negatively associated with all-cause mortality at age 80 and non-significantly or negatively associated in middle-to-older age groups. The original study authors noted that this observational association in older adults is confounded by reverse causality, wherein developing chronic illnesses cause cholesterol levels to drop prior to death.
A 2016 systematic review of observational cohort studies found no association between LDL cholesterol levels and cardiovascular disease in individuals aged 60 and older.
"So we looked at: was there first of all any association if you're over 60 with LDL cholesterol and heart disease? We found none." (said at 0:55:08)
A 2016 systematic review by Ravnskov and colleagues evaluated 19 cohort studies (30 cohorts, 68,094 individuals aged 60 and older) examining LDL cholesterol and mortality outcomes. Regarding cardiovascular mortality across 9 cohorts where it was assessed, seven cohorts found no association with LDL-C levels, and two cohorts found cardiovascular mortality was highest in the lowest LDL-C quartile. For all-cause mortality, an inverse association or lack of association was observed. Because this evidence is derived entirely from observational cohort studies prone to reverse causation and residual confounding, the certainty of evidence is low.
Low cholesterol levels are associated with an increased incidence of cancer.
"And we also know there is an association—I'll use this word, an association, right? Not definitely causal—between low cholesterol and cancer." (said at 0:55:50)
Epidemiological cohort studies have repeatedly demonstrated an observational association between low serum total cholesterol levels and an increased incidence or mortality of cancer. However, extensive research—including randomized intervention trials, long-term prospective cohorts, and Mendelian randomization analyses—indicates that this relationship is non-causal. Instead, the inverse association is largely explained by reverse causality (subclinical, undiagnosed malignancies consuming or suppressing serum lipids prior to diagnosis) and confounding factors such as underlying liver dysfunction or low albumin levels. Because the speaker explicitly qualified the statement as an observational association rather than a causal link, the statement accurately reflects the epidemiological evidence.
- supports: Low serum cholesterol, cancer and other noncardiovascular disorders. (Atherosclerosis 1992) · cited 30x in the literature
"A review of the evidence from ecological, cross-cultural comparisons, prospective epidemiological cohort studies and intervention trials provides no indication for a cause-and-effect association between low serum cholesterol or serum cholesterol lowering and the risk of cancer, except possibly at very low levels." (abstract, passage verified)
pubmedfull study (doi) - supports: Liver diseases and low serum albumin as potential confounders in the association between l… (Journal of clinical lipidology 2026)
"While cholesterol-lowering trials have consistently demonstrated cardiovascular disease (CVD) benefits, some observational studies showed an elevated mortality risk from all-cause, CVD, and cancer in those with low total cholesterol (TC)." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Review of the epidemiological evidence for a possible relationship between hypocholesterol… (Cancer research 1983) · cited 57x in the literature
"the available data do not substantiate any direct cause and effect relationship between low blood cholesterol levels and cancer. Rather, the data suggest that low cholesterol levels may serve as a "marker," possibly genetic, and in only small numbers of male individuals in any given population" (abstract, conclusions, passage verified)
pubmed
Fact-checked episodes
Publications